Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma

Huan Huan Wang, Nicholas G. Zaorsky, Mao Bin Meng, Zhi Qiang Wu, Xian Liang Zeng, Bo Jiang, Chao Jiang, Lu Jun Zhao, Zhi Yong Yuan, Ping Wang

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background and aim: Limited-stage combined small cell esophageal carcinoma (LS-C-SCEC) is a rare, poorly understood, underdiagnosed disease, with components of both small cell esophageal cancer and non–small cell esophageal cancer. We investigated the optimal treatment strategy and prognostic factors in patients with LS-C-SCEC. Patients and methods: LS-C-SCEC patients included in the analysis (from our hospital and the literature) were treated between January 1966 and December 2013. Patient treatment strategies included surgery (S), chemotherapy (CT), and radiation therapy (RT). The primary end point was overall survival (OS); the secondary end points included tumor complete response rates, patterns of failure, and toxicity. Kaplan–Meier curves were compared with the log-rank test. Univariate and multivariate analyses were used to determine prognosticators for OS. Results: A total of 72 patients were included in the analysis: 24 (33%) from our hospital and 48 (67%) from the literature. The median OS of all patients was 15.0 months. Patients who received CT had a significantly longer median OS than did those who did not (OS 22.8 months vs 10.0 months) (P=0.03). Patients treated with multimodality therapy (including RT+CT [18%], S+CT [40%], or S+RT+CT [17%]) vs monotherapy (typically, S [18%]) had significantly improved OS (15.5 months vs 9.3 months) (P=0.02) and complete response rates. On multivariate analysis, tumor location (upper third of the esophagus) and type of treatment (monotherapy) were the only factors predictive of poor OS. Conclusion: Multimodality therapy (including RT+CT, S+CT, or S+RT+CT) improves OS for patients with LS-C-SCEC compared with monotherapy (typically, S). Additional studies are necessary to personalize multimodal treatment approaches to individual patients.

Original languageEnglish (US)
Pages (from-to)437-444
Number of pages8
JournalOncoTargets and Therapy
StatePublished - Feb 13 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma'. Together they form a unique fingerprint.

Cite this